Get Started Today -
Call 1 800-770-9400
or click here for more info.

Watch How the
Kovanaze® Dental Alliance
Can Build Your Practice

KDA_circles_600-01
KDA_logo_800-01
Watch How the Kovanaze<sup>®</sup> Dental Alliance<sup>™</sup> Can Build Your Practice

As Powerful For Your Practice
As It Is For Your Patients

KDA_logo_800-01

Get Started Today - Call 1 800-770-9400 or click here for more info.

KDA_circles_600-01

Watch How the Kovanaze® Dental Alliance Can Build Your Practice

Watch How the Kovanaze<sup>®</sup> Dental Alliance<sup>™</sup> Can Build Your Practice

As Powerful For Your Practice As It Is For Your Patients

Engage new and existing patients with revolutionary no-needle Kovanaze® and state-of-the-art digital marketing powered by iHeartMedia. The Kovanaze® Dental Alliance (KDA) serves as your strategic partner in building your practice and providing the utmost in empathetic patient care. As a member of the KDA, you’ll receive a box of no-needle, FDA-approved Kovanaze® (tetracaine HCl and oxymetazoline HCl) Nasal Spray every quarter. Furthermore, you will gain access to the iHeartMedia network of more than 300,000 websites and 150,000 mobile apps, where your personalized 15 second video and 30 second audio spots will be promoted to thousands of patients within a five-mile radius of your practice. Your customized spots will target the specific demographic of patients you are trying to attract and will tout your status as an official Kovanaze® provider. Each month you’ll receive detailed reports tracking your results and measuring your ROI to ensure your marketing dollars achieve maximum impact. With the Kovanaze® Dental Alliance you can, quite literally, move the needle in your practice marketing. Enroll today with a NO-RISK, MONEY-BACK GUARANTEE!

Connect Your Practice to More Patients with the KDA and iHeartMedia

KDA_circle_graphic-01

Only the Kovanaze® Dental Alliance Can Deliver This Unbeatable Value Every Month

KDA_box_graphic-01

Enroll Today to Move the Needle in Your Practice Marketing!

Please enter your name.
Please enter a message.
Please check the captcha to verify you are not a robot.
DA_small@1x

Are you ready to take your practice promotion to the next level? Call or email your contact information to get started. We will send you all the information you need to put the Kovanaze® Dental Alliance to work for you.

or call 1 800 770-9400

Copyright © 2016 St. Renatus. All Rights Reserved.

Important Safety Information

IMPORTANT SAFETY INFORMATION: KOVANAZE is indicated for regional anesthesia when performing a restorative procedure on Teeth 4-13 and A-J in adults and children who weigh 40 kg or more. Use in patients with uncontrolled hypertension or inadequately controlled active thyroid disease of any type is not advised. Tetracaine may cause methemoglobinemia, particularly in conjunction with methemoglobin-inducing agents. Use of KOVANAZE in patients with a history of congenital or idiopathic methemoglobinemia is not advised. Methemoglobinemia should be considered if central cyanosis unresponsive to oxygen therapy occurs, especially if methemoglobinemia-inducing agents have been used. Confirm diagnosis by measuring methemoglobin level with co-oximetry. Treat clinically significant symptoms of methemoglobinemia with a standard clinical regimen. Allergic or anaphylactic reactions can occur. If an allergic reaction occurs, seek emergency help immediately. KOVANAZE is contraindicated in patients with a history of allergy to tetracaine, benzyl alcohol, other ester local anesthetics, p-aminobenzoic acid (PABA), oxymetazoline, or any other component of the product. Some clinical trial patients experienced an increase in blood pressure so blood pressure should be monitored. In addition, patients should be carefully monitored for dysphagia. KOVANAZE is not recommended for use in patients with a history of frequent nose bleeds. Concomitant use of monoamine oxidase inhibitors, nonselective beta adrenergic antagonist, or tricyclic antidepressants may cause hypertension and is not recommended. Discontinue use of oxymetazoline-containing products 24 hours prior to KOVANAZE administration. Avoid concomitant use of intranasal products. The most common adverse reactions to KOVANAZE occurring in >10% of patients include a runny nose, nasal congestion, nasal discomfort, sore throat, and watery eyes.

Click here for full Prescribing Information: Package Insert

IMPORTANT SAFETY INFORMATION: Use in patients with uncontrolled hypertension or inadequately controlled active thyroid disease of any type is not advised. Tetracaine may cause methemoglobinemia, particularly in conjunction with methemoglobin-inducing agents. Use of KOVANAZE in patients with a history of congenital or idiopathic methemoglobinemia is not advised. Methemoglobinemia should be considered if central cyanosis unresponsive to oxygen therapy occurs, especially if methemoglobinemia-inducing agents have been used. Confirm diagnosis by measuring methemoglobin level with co-oximetry. Treat clinically significant symptoms of methemoglobinemia with a standard clinical regimen. Allergic or anaphylactic reactions can occur. If an allergic reaction occurs, seek emergency help immediately. KOVANAZE is contraindicated in patients with a history of allergy to tetracaine, benzyl alcohol, other ester local anesthetics, p-aminobenzoic acid (PABA), oxymetazoline, or any other component of the product. Some clinical trial patients experienced an increase in blood pressure so blood pressure should be monitored. In addition, patients should be carefully monitored for dysphagia. KOVANAZE is not recommended for use in patients with a history of frequent nose bleeds. Concomitant use of monoamine oxidase inhibitors, nonselective beta adrenergic antagonist, or tricyclic antidepressants may cause hypertension and is not recommended. Discontinue use of oxymetazoline-containing products 24 hours prior to KOVANAZE administration. Avoid concomitant use of intranasal products. The most common adverse reactions to KOVANAZE occurring in >10% of patients include a runny nose, nasal congestion, nasal discomfort, sore throat, and watery eyes.

Click here for full Prescribing Information: Package Insert